{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:46:29Z","timestamp":1793850389836,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05908-4","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:57:37Z","timestamp":1722257857000},"page":"4065-4077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["MoReLife \u2013 real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1774-7605","authenticated-orcid":false,"given":"Stefanie","family":"Jilg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Sockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl C.","family":"Crodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeska","family":"Brueckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Moyses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Caduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lino L.","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-8266","authenticated-orcid":false,"given":"Florian","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa K.","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Petro E.","family":"Petrides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"6","key":"5908_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667\u2013679. https:\/\/doi.org\/10.1182\/blood-2016-10-695940","journal-title":"Blood"},{"key":"5908_CR2","doi-asserted-by":"publisher","unstructured":"Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP, Sabattini E, Gianelli U (2021) The classification of Myeloproliferative neoplasms: Rationale, historical background and future perspectives with focus on unclassifiable cases. Cancers (Basel) 13(22). https:\/\/doi.org\/10.3390\/cancers13225666","DOI":"10.3390\/cancers13225666"},{"issue":"3","key":"5908_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ejh.13198","volume":"102","author":"G Birgegard","year":"2019","unstructured":"Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W, Hasselbalch H, Nielsen CH, Knutsen H, Pedersen OB, Sorensen A, Andreasson B (2019) Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the nordic MPN study Group. Eur J Haematol 102(3):235\u2013240. https:\/\/doi.org\/10.1111\/ejh.13198","journal-title":"Eur J Haematol"},{"issue":"9","key":"5908_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"9","key":"5908_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"5908_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, Investigators C (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139\u20131145. https:\/\/doi.org\/10.3324\/haematol.2014.119545","journal-title":"Haematologica"},{"issue":"25","key":"5908_CR7","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","volume":"115","author":"JW Tyner","year":"2010","unstructured":"Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115(25):5232\u20135240. https:\/\/doi.org\/10.1182\/blood-2009-05-223727","journal-title":"Blood"},{"issue":"1","key":"5908_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3324\/haematol.2016.148924","volume":"102","author":"V Gupta","year":"2017","unstructured":"Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S (2017) A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102(1):94\u2013102. https:\/\/doi.org\/10.3324\/haematol.2016.148924","journal-title":"Haematologica"},{"issue":"6","key":"5908_CR9","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/leu.2013.71","volume":"27","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A (2013) Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27(6):1322\u20131327. https:\/\/doi.org\/10.1038\/leu.2013.71","journal-title":"Leukemia"},{"issue":"13","key":"5908_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P, Fowles P, Burns CJ, Smith G, Wagner KU, Weiss G, Whitney JA, Theurl I (2017) Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129(13):1823\u20131830. https:\/\/doi.org\/10.1182\/blood-2016-09-740092","journal-title":"Blood"},{"key":"5908_CR11","doi-asserted-by":"publisher","unstructured":"Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R (2024) Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 1\u201313. https:\/\/doi.org\/10.1080\/10428194.2024.2328800","DOI":"10.1080\/10428194.2024.2328800"},{"issue":"10373","key":"5908_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R, Investigators MS (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0","journal-title":"Lancet"},{"issue":"9","key":"5908_CR13","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","volume":"10","author":"AT Gerds","year":"2023","unstructured":"Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 10(9):e735\u2013e746. https:\/\/doi.org\/10.1016\/S2352-3026(23)00174-6","journal-title":"Lancet Haematol"},{"issue":"14","key":"5908_CR14","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","volume":"7","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C (2023) Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv 7(14):3582\u20133591. https:\/\/doi.org\/10.1182\/bloodadvances.2022009311","journal-title":"Blood Adv"},{"issue":"34","key":"5908_CR15","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418","journal-title":"J Clin Oncol"},{"issue":"13","key":"5908_CR16","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"1","key":"5908_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 87(1):25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","journal-title":"Mayo Clin Proc"},{"key":"5908_CR18","doi-asserted-by":"publisher","first-page":"100716","DOI":"10.1016\/j.blre.2020.100716","volume":"42","author":"RM Scherber","year":"2020","unstructured":"Scherber RM, Mesa RA (2020) Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression. Blood Rev 42:100716. https:\/\/doi.org\/10.1016\/j.blre.2020.100716","journal-title":"Blood Rev"},{"key":"5908_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/TCRM.S258704","volume":"16","author":"S Bassiony","year":"2020","unstructured":"Bassiony S, Harrison CN, McLornan DP (2020) Evaluating the Safety, Efficacy, and therapeutic potential of Momelotinib in the treatment of Intermediate\/High-Risk myelofibrosis: evidence to date. Ther Clin Risk Manag 16:889\u2013901. https:\/\/doi.org\/10.2147\/TCRM.S258704","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"5908_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","volume":"97","author":"AT Kuykendall","year":"2018","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435\u2013441. https:\/\/doi.org\/10.1007\/s00277-017-3194-4","journal-title":"Ann Hematol"},{"issue":"1","key":"5908_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","volume":"1","author":"L Naymagon","year":"2017","unstructured":"Naymagon L, Mascarenhas J (2017) Myelofibrosis-related Anemia: current and emerging therapeutic strategies. Hemasphere 1(1):e1. https:\/\/doi.org\/10.1097\/HS9.0000000000000001","journal-title":"Hemasphere"},{"issue":"1","key":"5908_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3324\/haematol.2010.031831","volume":"96","author":"C Elena","year":"2011","unstructured":"Elena C, Passamonti F, Rumi E, Malcovati L, Arcaini L, Boveri E, Merli M, Pietra D, Pascutto C, Lazzarino M (2011) Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 96(1):167\u2013170. https:\/\/doi.org\/10.3324\/haematol.2010.031831","journal-title":"Haematologica"},{"issue":"1","key":"5908_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15(1):7. https:\/\/doi.org\/10.1186\/s13045-021-01157-4","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5908_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.clinthera.2014.02.016","volume":"36","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM (2014) Use of the Functional Assessment of Cancer therapy\u2013anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther 36(4):560\u2013566. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.016","journal-title":"Clin Ther"},{"issue":"1","key":"5908_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"key":"5908_CR26","doi-asserted-by":"publisher","unstructured":"Rumi E, Trotti C, Vanni D, Casetti IC, Pietra D, Sant\u2019Antonio E (2020) The genetic basis of primary myelofibrosis and its clinical relevance. Int J Mol Sci 21(23). https:\/\/doi.org\/10.3390\/ijms21238885","DOI":"10.3390\/ijms21238885"},{"issue":"9","key":"5908_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","volume":"18","author":"J How","year":"2020","unstructured":"How J, Hobbs GS (2020) A practical guide for using myelofibrosis prognostic models in the clinic. J Natl Compr Canc Netw 18(9):1271\u20131278. https:\/\/doi.org\/10.6004\/jnccn.2020.7557","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"5908_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A (2018) Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32(5):1254\u20131258. https:\/\/doi.org\/10.1038\/s41375-018-0028-x","journal-title":"Leukemia"},{"issue":"2","key":"5908_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/MOH.0000000000000794","volume":"31","author":"EA Griffiths","year":"2024","unstructured":"Griffiths EA (2024) Transfusion avoidance in myelodysplastic neoplasms. Curr Opin Hematol 31(2):40\u201346. https:\/\/doi.org\/10.1097\/MOH.0000000000000794","journal-title":"Curr Opin Hematol"},{"issue":"19","key":"5908_CR30","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","volume":"7","author":"ST Oh","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S (2023) Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 7(19):5835\u20135842. https:\/\/doi.org\/10.1182\/bloodadvances.2023010151","journal-title":"Blood Adv"},{"issue":"2","key":"5908_CR31","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73\u2013e81. https:\/\/doi.org\/10.1016\/S2352-3026(17)30237-5","journal-title":"Lancet Haematol"},{"issue":"1","key":"5908_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41408-024-01028-4","volume":"14","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Pardanani A, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Ketterling RP, Reichard KK, Gangat N (2024) Calr type 1\/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant. Blood Cancer J 14(1):51. https:\/\/doi.org\/10.1038\/s41408-024-01028-4","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05908-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05908-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:05:38Z","timestamp":1729933538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05908-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5908"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05908-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the analysis was retrospective and pseudonymized, the Research Ethics Committee of the Ludwig Maximilians University of Munich confirmed that no additional ethical approval was required. However, each center obtained an informed consent for the participation in this analysis. All data were analyzed descriptively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}